デフォルト表紙
市場調査レポート
商品コード
1597834

T細胞療法市場:モダリティ、治療タイプ、適応症別-2025~2030年の世界予測

T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 184 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円
T細胞療法市場:モダリティ、治療タイプ、適応症別-2025~2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

T細胞療法市場は、2023年に81億3,000万米ドルと評価され、2024年には98億5,000万米ドルに達すると予測され、CAGR 21.23%で成長し、2030年には313億米ドルになると予測されています。

T細胞療法は、免疫療法の重要な一面であり、がん細胞を標的として破壊するために遺伝子組み換えT細胞を利用するもので、現代のがん治療において大きな可能性を示しています。その必要性は、従来の治療に反応しない腫瘍に対処する能力にあり、個別化治療の選択肢を記載しています。その用途と最終用途は、白血病やリンパ腫などの血液がんから固形がんにまで及び、病院、研究機関、バイオテクノロジー企業に及んでいます。市場成長の主要要因は、CAR-T療法やTCR療法の進歩、バイオテクノロジーへの投資の増加、がん罹患率の上昇です。しかし、生産コスト、複雑な規制状況、潜在的な副作用は、成長を妨げる顕著な制限となっています。最新のビジネス機会は、T細胞の有効性を高めるCRISPRのような遺伝子編集技術の進歩や、自己免疫疾患のような非腫瘍学的用途への拡大から生じています。このような機会を活用するためには、製造プロセスの合理化とコスト削減のために、バイオテクノロジー企業と学術機関が協力することが推奨されます。さらに、新規のベクターシステムや送達方法による安全性プロファイルの改善に注力することで、規制上の課題や社会的懸念に対処することができます。このような展望にもかかわらず、市場は高い治療費、凍結保存細胞輸送のロジスティクス、安全性と有効性を確保するための大規模臨床検査の必要性といったハードルに直面しています。技術革新は、製造時間とコストを削減できる同種T細胞の開発や、標的同定の精度を高め、精密医療を保証する次世代シークエンシング手法の活用といったセグメントで盛んになる可能性があります。さらに、患者選択と治療法のカスタマイズに人工知能を活用することで、最適化された治療結果を得ることができます。市場力学は、急速な技術進歩に伴い非常にダイナミックであるため、利害関係者が競合を維持するためには、進化する研究開発の最前線に機敏に対応し続けることが極めて重要です。

主要市場の統計
基準年[2023年] 81億3,000万米ドル
予測年[2024年] 98億5,000万米ドル
予測年[2030年] 313億米ドル
CAGR(%) 21.23%

市場力学:急速に進化するT細胞療法市場の主要市場洞察を公開

T細胞療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 製造能力の拡大に伴う承認の増加
    • がん有病率の驚くべき増加率
    • 政府の認識による適切な償還の利用可能性
  • 市場抑制要因
    • CAR T細胞免疫療法の有効性の限界と、腫瘍沈着部へのCAR-T細胞のホーミングの不十分さ
  • 市場機会
    • 免疫腫瘍学セグメントへの研究開発費の急増
    • 遺伝子・細胞治療の採用拡大
  • 市場課題
    • 安全性の問題と副作用の可能性

ポーターのファイブフォース:T細胞療法市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:T細胞療法市場における外部からの影響の把握

外部マクロ環境要因は、T細胞療法市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析:T細胞療法市場における競合情勢の把握

T細胞療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス:T細胞療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、T細胞療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨:T細胞療法市場における成功への道筋を描く

T細胞療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度:新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化:最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、地域はどこか?

3.市場を形成する主要技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 製造能力の拡大とともに承認も増加
      • がん罹患率の驚くべき増加率
      • 政府の認識別の適切な補償の提供
    • 抑制要因
      • CAR-T細胞免疫療法の有効性の限界とCAR T細胞の腫瘍沈着への不十分なホーミング
    • 機会
      • 免疫腫瘍学セグメントへの研究開発資金の急増
      • 遺伝子・細胞治療の導入拡大
    • 課題
      • 安全性の問題と起こりうる副作用
  • 市場セグメンテーション分析
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 法律
    • 環境

第6章 T細胞療法市場:モダリティ別

  • イントロダクション
  • 商業化
  • 研究

第7章 T細胞療法市場:治療タイプ別

  • イントロダクション
  • CAR-T細胞療法
  • T細胞受容体ベース
  • 腫瘍浸潤リンパ球ベース

第8章 T細胞療法市場:適応症別

  • イントロダクション
  • 造血悪性腫瘍
    • 白血病
    • リンパ腫
    • 骨髄腫
  • 固形腫瘍
    • 脳と中枢神経系
    • 肝臓がん
    • 悪性黒色腫

第9章 南北アメリカのT細胞療法市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋のT細胞療法市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのT細胞療法市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析、2023年
  • FPNVポジショニングマトリックス、2023年
  • 競合シナリオ分析
  • 戦略分析と提言

企業一覧

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Amgen Inc.
  • Bluebird Bio, Inc.
  • Bristol Myers Squibb
  • DiaCarta, Inc.
  • Fate Therapeutics Inc.
  • Gilead Sciences, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Poseida Therapeutics Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Tessa Therapeutics Pte. Ltd.
図表

LIST OF FIGURES

  • FIGURE 1. T-CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. T-CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. T-CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY COMMERCIALIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY T CELL RECEPTOR-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 234. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-A26E0E5744D4

The T-Cell Therapy Market was valued at USD 8.13 billion in 2023, expected to reach USD 9.85 billion in 2024, and is projected to grow at a CAGR of 21.23%, to USD 31.30 billion by 2030.

T-cell therapy, a pivotal facet of immunotherapy, utilizes genetically modified T-cells to target and destroy cancer cells, presenting significant potential in modern oncology treatments. Its necessity lies in its ability to address tumors unresponsive to conventional therapies, offering personalized treatment options. The application and end-use scope range from blood cancers, such as leukemia and lymphoma, to solid tumors, spanning hospitals, research institutes, and biotech companies. Market growth is predominantly driven by advancements in CAR-T and TCR therapies, increased investment in biotechnology, and rising cancer prevalence. However, production cost, complex regulatory landscapes, and potential side effects serve as notable limitations hindering growth. The latest opportunities arise from advances in gene editing technologies like CRISPR, which could enhance T-cell efficacy, and expansion into non-oncological applications, such as autoimmune diseases. To capitalize on these opportunities, collaboration between biotech firms and academic institutions to streamline manufacturing processes and mitigate costs is recommended. Moreover, focusing on improving safety profiles through novel vector systems and delivery methods can address regulatory challenges and public concerns. Despite these prospects, the market faces hurdles in terms of high therapy costs, logistics of cryopreserved cell transport, and the need for extensive clinical trials to ensure safety and efficacy. Innovation can thrive in areas like developing allogeneic T-cells, which could reduce manufacturing time and cost, and harnessing next-generation sequencing methods for better target identification, ensuring precision medicine. Additionally, tapping into artificial intelligence for patient selection and therapy customization can yield optimized outcomes. The nature of the market is highly dynamic, with rapid technological progress, making it crucial for stakeholders to remain agile and responsive to evolving research and development fronts to maintain a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 8.13 billion
Estimated Year [2024] USD 9.85 billion
Forecast Year [2030] USD 31.30 billion
CAGR (%) 21.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving T-Cell Therapy Market

The T-Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing approvals along with expanding manufacturing capabilities
    • Alarming rate of increase in prevalence of cancers
    • Availability of adequate reimbursements with government awareness
  • Market Restraints
    • Limitations of efficacy of CAR T-cell immunotherapy and inadequate homing of CAR T-cells to tumor deposits
  • Market Opportunities
    • Exponential R&D funding for immuno-oncology sector
    • Expanding adoption of gene and cell therapy
  • Market Challenges
    • Safety issues and possible side-effects

Porter's Five Forces: A Strategic Tool for Navigating the T-Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the T-Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the T-Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the T-Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the T-Cell Therapy Market

A detailed market share analysis in the T-Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the T-Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the T-Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the T-Cell Therapy Market

A strategic analysis of the T-Cell Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Amgen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, DiaCarta, Inc., Fate Therapeutics Inc., Gilead Sciences, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Poseida Therapeutics Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., and Tessa Therapeutics Pte. Ltd..

Market Segmentation & Coverage

This research report categorizes the T-Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Modality, market is studied across Commercialized and Research.
  • Based on Therapy Type, market is studied across CAR T-cell Therapy, T Cell Receptor-Based, and Tumor Infiltrating Lymphocytes-Based.
  • Based on Indication, market is studied across Hematologic Malignancies and Solid Tumors. The Hematologic Malignancies is further studied across Leukemia, Lymphoma, and Myeloma. The Solid Tumors is further studied across Brain & Central Nervous System, Liver Cancer, and Melanoma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing approvals along with expanding manufacturing capabilities
      • 5.1.1.2. Alarming rate of increase in prevalence of cancers
      • 5.1.1.3. Availability of adequate reimbursements with government awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations of efficacy of CAR T-cell immunotherapy and inadequate homing of CAR T-cells to tumor deposits
    • 5.1.3. Opportunities
      • 5.1.3.1. Exponential R&D funding for immuno-oncology sector
      • 5.1.3.2. Expanding adoption of gene and cell therapy
    • 5.1.4. Challenges
      • 5.1.4.1. Safety issues and possible side-effects
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. T-Cell Therapy Market, by Modality

  • 6.1. Introduction
  • 6.2. Commercialized
  • 6.3. Research

7. T-Cell Therapy Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. CAR T-cell Therapy
  • 7.3. T Cell Receptor-Based
  • 7.4. Tumor Infiltrating Lymphocytes-Based

8. T-Cell Therapy Market, by Indication

  • 8.1. Introduction
  • 8.2. Hematologic Malignancies
    • 8.2.1. Leukemia
    • 8.2.2. Lymphoma
    • 8.2.3. Myeloma
  • 8.3. Solid Tumors
    • 8.3.1. Brain & Central Nervous System
    • 8.3.2. Liver Cancer
    • 8.3.3. Melanoma

9. Americas T-Cell Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific T-Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa T-Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adaptimmune Therapeutics PLC
  • 3. Amgen Inc.
  • 4. Bluebird Bio, Inc.
  • 5. Bristol Myers Squibb
  • 6. DiaCarta, Inc.
  • 7. Fate Therapeutics Inc.
  • 8. Gilead Sciences, Inc.
  • 9. Merck KGaA
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Poseida Therapeutics Inc.
  • 13. Sorrento Therapeutics, Inc.
  • 14. Takara Bio Inc.
  • 15. Tessa Therapeutics Pte. Ltd.